PS 14-41 SINGLE-PILL TRIPLE COMBINATION OF PERINDOPRIL/INDAPAMIDE/AMLODIPINE IN PATIENTS WITH ESSENTIAL HYPERTENSION: SERBIAN EXPERIENCE. (September 2016)

• Record Type: Journal Article
• Authors: Tasic, Nebojsa; Tasic, Danijela; Balevic, Milijana; Dragisic, Dalibor
• Is Part Of: Journal of hypertension. Volume 34:(2016) Supplement 1
• Publication Date: 2016-09
• Subjects: Hypertension -- Periodicals; Hypertension -- Periodicals; 616.132005
• DOI: 10.1097/01.hjh.0000501163.78001.6e
• Languages: English
• ISSNs: 1473-5598

Abstract

Abstract : Objective: Hypertension is the major risk factor in Serbia for the morbidity and mortality of cardiovascular and cerebrovascular diseases. The majority of patients in Serbia need two or more antihypertensive drugs for adequate control of blood pressure. Design and Method: Study group consisted of 12 patients with uncontrolled essential hypertension without comorbidities randomized in two groups and followed for 12 weeks. The first group was treated with single-pill combination perindopril 5 mg/indapamide 1.25 mg and an additional tablet of amlodipine 5 mg. The second group received single-pill triple combination of perindopril 5 mg/indapamide 1.25 mg/amlodipine 5 mg. Results: Our research showed a significant decrease in systolic (132.5 vs. 140.5 mmHg, P = 0.05) and diastolic (84.50 vs. 83.83 mmHg, P < 0.05) blood pressure from baseline (153/84.50 mmHg vs. 149.17/94 mmHg) in both groups after 12 weeks of treatment. There was a higher proportion of patients achieving target blood pressure (<140/90 mmHg) in the single-pill triple combination group (69.7%) in comparison with the other group (50%). Conclusions: Our results showed significant reductions in blood pressure and a high BP control rate with the single-pill triple combination perindropil/amlodipine/indapamide in patients with uncontrolled essential hypertension without comorbidities.